The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.
 
Guillaume Joe Pegna
No Relationships to Disclose
 
Mehwish Iqra Ahmad
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Cody J. Peer
No Relationships to Disclose
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
David JP FitzGerald
Stock and Other Ownership Interests - AMT Biopharma
Patents, Royalties, Other Intellectual Property - National Institute of Health (NIH) (Inst)
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Mesothelin domain-specific monoclonal antibodies and use thereof (Patent number:9803022)
 
Ira Pastan
No Relationships to Disclose
 
Christine Alewine
No Relationships to Disclose